ALPRAZOLAM Drug Patent Profile

Which patents cover Alprazolam, and when can generic versions of Alprazolam launch?

Alprazolam is a drug marketed by Hikma, Roxane, Actavis Elizabeth, Actavis Labs Fl Inc, Amneal Pharms Ny, Ani Pharms, Apotex Inc, Aurobindo Pharma, Heritage Pharms Inc, Impax Labs, Impax Labs Inc, Ph Health, Pharmobedient, Sandoz Inc, Chartwell Rx, Ivax Sub Teva Pharms, Mylan, Natco, Novitium Pharma, Oxford Pharms, Sandoz, Strides Pharma Intl, Sun Pharm, and Watson Labs. and is included in thirty-six NDAs.

The generic ingredient in ALPRAZOLAM is alprazolam. There are fifteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the alprazolam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alprazolam

A generic version of ALPRAZOLAM was approved as alprazolam by NOVITIUM PHARMA on October 19^th, 1993.

Summary for ALPRAZOLAM

US Patents:	0
Applicants:	24
NDAs:	36
Finished Product Suppliers / Packagers:	28
Raw Ingredient (Bulk) Api Vendors:	47
Clinical Trials:	105
Patent Applications:	4,302
Drug Prices:	Drug price information for ALPRAZOLAM
Drug Sales Revenues:	Drug sales revenues for ALPRAZOLAM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ALPRAZOLAM
What excipients (inactive ingredients) are in ALPRAZOLAM?	ALPRAZOLAM excipients list
DailyMed Link:	ALPRAZOLAM at DailyMed

See drug prices for ALPRAZOLAM

See drug sales revenues for ALPRAZOLAM

Recent Clinical Trials for ALPRAZOLAM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi	NA
University of California, San Francisco	PHASE4
UCB Biopharma SRL	PHASE1

See all ALPRAZOLAM clinical trials

Pharmacology for ALPRAZOLAM

Drug Class

Benzodiazepine

Medical Subject Heading (MeSH) Categories for ALPRAZOLAM

Anti-Anxiety Agents

GABA Modulators

Hypnotics and Sedatives

Anatomical Therapeutic Chemical (ATC) Classes for ALPRAZOLAM

N05BA	Benzodiazepine derivatives
N05B	ANXIOLYTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for ALPRAZOLAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NIRAVAM	Orally Disintegrating Tablets	alprazolam	0.25 mg, 0.5 mg, 1 mg and 2 mg	021726	1	2005-12-27

US Patents and Regulatory Information for ALPRAZOLAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	ALPRAZOLAM	alprazolam	TABLET;ORAL	074085-002	Feb 16, 1994		DISCN	No	No
Novitium Pharma	ALPRAZOLAM	alprazolam	TABLET;ORAL	074174-003	Oct 19, 1993	AB	RX	No	No
Impax Labs Inc	ALPRAZOLAM	alprazolam	TABLET, EXTENDED RELEASE;ORAL	077996-003	Jan 31, 2007		DISCN	No	No
Heritage Pharms Inc	ALPRAZOLAM	alprazolam	TABLET, EXTENDED RELEASE;ORAL	078489-002	Oct 17, 2008		DISCN	No	No
Chartwell Rx	ALPRAZOLAM	alprazolam	TABLET;ORAL	207507-004	Jul 9, 2018		DISCN	No	No
Sandoz	ALPRAZOLAM	alprazolam	TABLET;ORAL	074112-001	Dec 29, 1995	AB	RX	No	No

Market Dynamics and Financial Trajectory for Alprazolam

Last updated: February 19, 2026

What is the current market size and growth trend for alprazolam?

Alprazolam, a benzodiazepine primarily used to treat anxiety and panic disorders, has a significant market presence. The global anxiolytics market, which includes benzodiazepines like alprazolam, was valued at approximately USD 6.2 billion in 2022, with a compound annual growth rate (CAGR) of about 2.4% projected through 2030 [1].

While specific market share data for alprazolam is limited due to patent expirations and generic proliferation, it accounts for an estimated 60-70% of the benzodiazepine market in the U.S. [2].

How have patent expirations and generic competition affected revenue?

Alprazolam's patent expired in the late 1990s, resulting in widespread generic manufacturing. This transition significantly reduced per-unit pricing, leading to an overall decline in branded sales.

In the U.S., branded alprazolam formulations saw peak revenues of USD 600 million annually in the early 2000s. Currently, branded sales represent less than USD 50 million, with generics dominating the market [3].

What are the key regional markets for alprazolam?

• United States: Largest market; high prescription volume. However, increased regulatory scrutiny and a shift towards newer anxiolytics impact growth.
• Europe: Moderate growth; regulatory hurdles and alternative therapies limit market expansion.
• Asia-Pacific: Emerging market; demand driven by increasing mental health awareness and healthcare infrastructure development. Nevertheless, regulatory and patent issues affect availability.

What regulatory policies influence market access?

The U.S. Food and Drug Administration (FDA) classifies alprazolam as a controlled substance (Schedule IV), impacting prescribing practices and pharmacy distribution.

The Drug Enforcement Administration (DEA) enforces strict manufacturing and dispensing controls, affecting supply chains.

Europe’s regulatory landscape varies by country but generally imposes strict controls under the European Medicines Agency (EMA), impacting market access.

Emerging markets face regulatory and licensing delays, impacting timely entry and revenue realization.

What financial trends are anticipated for alprazolam?

Given the expiration of patents and growth in alternatives, revenue for branded alprazolam declines. However, the total market maintains stability due to continued demand for generic formulations.

Manufacturers invest minimally in R&D for new formulations due to low profitability prospects. Sales are primarily driven by existing formulations.

Pricing pressures persist due to increased generics competition. Market revenues are projected to decline at a CAGR of approximately 1-2% over the next five years [4].

How does the competitive landscape influence future revenue?

Key generic manufacturers include Teva, Mylan, and Sandoz. They produce cost-competitive formulations in multiple markets.

Innovative or branded strategies are limited, given the drug’s age and market saturation.

The potential introduction of new anxiolytics, such as selective serotonin reuptake inhibitors (SSRIs), presents a threat to market share.

Specialty markets or formulations (e.g., extended-release versions) may offer niche opportunities but face regulatory challenges.

What role do clinical guidelines and cultural factors play?

Clinical guidelines increasingly favor non-benzodiazepine medications for anxiety due to addiction and dependency risks associated with alprazolam [5].

Cultural shifts toward non-pharmacologic therapies could temper future demand.

Summary of Market and Financial Outlook

Aspect	Current Status	Future Considerations
Market size	USD 6.2 billion (2022)	Slight decline; 1-2% CAGR forecast
Key markets	U.S., Europe, Asia-Pacific	Regional growth variations influenced by regulation, access
Patent status	Expired in late 1990s	Market dominated by generics
Revenue trends	Peak USD 600 million; now below USD 50 million branded	Declining branded revenue; stable generic volume
Regulatory environment	Strict controls under FDA, EMA	Potential for increased regulation impacting supply
Competition	Major generics manufacturers	High price competition; limited innovation

Key Takeaways

• The alprazolam market is mature, with revenues primarily driven by generics after patent expiry.
• Revenue is declining due to increased competition and regulatory control.
• North American markets dominate, with emerging opportunities in Asia-Pacific.
• Regulatory policies heavily influence market access and manufacturing.
• Demand shifts toward non-benzodiazepine therapies threaten long-term stability.

Frequently Asked Questions

1. How does patent expiry impact alprazolam revenues?
Patent expiry leads to generic manufacturing, reducing prices and branded sales, often causing revenue declines in the branded segment.

2. Are there new formulations of alprazolam in development?
No significant new formulations are under development for alprazolam; market focus has shifted toward newer anxiolytics and non-pharmacological treatments.

3. What regulatory hurdles exist for potential new entrants?
Controlled substance scheduling under agencies like the DEA and EMA limits manufacturing and prescribing. Approvals require strict compliance, and existing market saturation reduces incentives.

4. How is the rise of alternative therapies affecting the market?
Guidelines favor SSRIs and cognitive-behavioral therapy, reducing alprazolam prescriptions and long-term market stability.

5. What is the outlook for alprazolam in emerging markets?
Growing mental health awareness creates opportunities, but regulatory barriers and supply chain complexities remain significant hurdles.

---

References

[1] MarketWatch. (2022). "Global anxiolytics market size and forecast."
[2] IQVIA. (2021). "Benzodiazepine market share analysis."
[3] IMS Health. (2004). "Revenue trends for alprazolam."
[4] Grand View Research. (2023). "Pharmaceutical market forecasts."
[5] NICE. (2019). "Guidelines for anxiety treatment."

Note: Data cited from publicly available reports and industry analyses.